請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26620
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 高純琇(Churn-Shiouh Gau) | |
dc.contributor.author | Yi-shiu Lin | en |
dc.contributor.author | 林怡琇 | zh_TW |
dc.date.accessioned | 2021-06-08T07:17:48Z | - |
dc.date.copyright | 2008-08-14 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-25 | |
dc.identifier.citation | 1. World Health Organization. 2008. (Accessed at http://www.who.int/topics/diabetes_mellitus/en/.)
2. 行政院衛生署衛生統計資訊網. 2008. (Accessed at http://www.doh.gov.tw/statistic/index.htm.) 3. American Diabetes Association 2008. (Accessed 20080313, at http://www.diabetes.org/diabetes-statistics.jsp.) 4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53. 5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-65. 6. U.S. Food and Drug Administration. 2007. (Accessed at http://www.fda.gov/medwatch/index.html ) 7. Avorn J. Too sweet to be true. In: J. A, ed. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Vintage Books; 2005:85-95. 8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71. 9. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004;27(7):1647-53. 10. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279-89. 11. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28(7):1547-54. 12. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002;24(3):378-96. 13. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53. 14. International Diabetes Federation: The Diabetes Atlas Executive Summary. 2008. (Accessed at http://www.eatlas.idf.org/webdata/docs/Atlas%202003-Summary.pdf.) 15. 糖尿病專業醫療服務品質報告. 2008. (Accessed at http://www.nhi.gov.tw/webdata/webdata.asp?menu=1&menu_id=&webdata_ID=848.) 16. American Diabetes Association /American College of Cardiology. Diabetes Cardiovascular Disease Review. Redefining Diabetes Control. 2008(1). 17. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998;21(7):1138-45. 18. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339(4):229-34. 19. Schramm TK, Gislason GH, Kober L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008;117(15):1945-54. 20. Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004;109(7):855-60. 21. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999;22(7):1077-83. 22. Wagenknecht LE, D'Agostino R, Jr., Savage PJ, O'Leary DH, Saad MF, Haffner SM. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997;28(5):999-1005. 23. Wagenknecht LE, D'Agostino RB, Jr., Haffner SM, Savage PJ, Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1998;21(11):1812-8. 24. Haffner SM, Agostino RD, Jr., Saad MF, et al. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol 2000;85(12):1395-400. 25. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34(1):29-34. 26. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24(9):1614-9. 27. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC, Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27(3):699-703. 28. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22(4 Suppl A):6A-13A. 29. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77(11):1017-20. 30. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14(1):49-57. 31. Standards of medical care in diabetes--2008. Diabetes Care 2008;31 Suppl 1:S12-54. 32. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13 Suppl 1:1-68. 33. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29(8):1963-72. 34. AHFS Drug Information. 2008. (Accessed at http://online.statref.com/Document/Document.aspx?DocId=982&FxId=1&Scroll=347&Index=0&SessionId=BF22A7POUMOMVREV.) 35. Micromedex® Healthcare Series, (electronic version). Thomson Micromedex. (Accessed 4/20, 2007, at http://www.thomsonhc.com.) 36. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? Int J Obes Relat Metab Disord 2000;24 Suppl 3:S21-31. 37. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23(11):1660-5. 38. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000;23(2):202-7. 39. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351(11):1106-18. 40. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292(3):E871-83. 41. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23(11):1605-11. 42. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12(5):413-23. 43. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003;25(4):1074-95. 44. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22(12):1395-409. 45. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111(1):10-7. 46. Jovanovic L, Hassman DR, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004;63(2):127-34. 47. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005;27(5):554-67. 48. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43. 49. Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther 2007;29(9):1900-14. 50. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24(7):1226-32. 51. Hollander P, Yu D, Chou HS. Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes. Arch Intern Med 2007;167(12):1284-90. 52. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86(1):280-8. 53. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24(2):308-15. 54. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283(13):1695-702. 55. Vongthavaravat V, Wajchenberg BL, Waitman JN, et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin 2002;18(8):456-61. 56. Hanefeld M, Patwardhan R, Jones NP. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis 2007;17(1):13-23. 57. Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26(5):744-54. 58. Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31(4):375-83. 59. Baba T, Shimada K, Neugebauer S, Yamada D, Hashimoto S, Watanabe T. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 2001;24(5):953-4. 60. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007;30(9):741-53. 61. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108(23):2941-8. 62. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370(9593):1129-36. 63. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003;26(11):2983-9. 64. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med 2007;357(1):28-38. 65. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003;115 Suppl 8A:42S-8S. 66. Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother 2007;41(12):2014-8. 67. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008;19(2):129-37. 68. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146(3):1226-35. 69. Re: Clinical Trial Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with Avandia® (rosiglitazone maleate) Tablets for Type 2 Diabetes Mellitus. 2007. (Accessed at http://www.fda.gov/medwatch/safety/2007/Avandia_GSK_Ltr.pdf.) 70. Re: Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with ACTOSO (pioglitazone HOI) Tablets for Type 2 Diabetes Mellitus. 2007. (Accessed at http://www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf.) 71. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976;25(12):1129-53. 72. Fisman EZ, Tenenbaum A, Motro M, Adler Y. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Herz 2004;29(3):290-8. 73. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978;240(1):37-42. 74. Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM? Diabetologia 1995;38(1):116-21. 75. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj 2000;321(7258):405-12. 76. Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(12A):34i-43i. 77. Komajda M, Curtis P, Hanefeld M, et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol 2008;7(1):10. 78. Donnelly R. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes. Int J Clin Pract 2007;61(7):1160-9. 79. Dolezalova R, Haluzik MM, Bosanska L, et al. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiol Res 2007;56(6):741-8. 80. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106(6):679-84. 81. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003;42(10):1757-63. 82. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296(21):2572-81. 83. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004;24(5):930-4. 84. Bhatt DL, Chew DP, Grines C, et al. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. Am Heart J 2007;154(1):137-43. 85. ZM2005/00181/01: Avandia Cardiovascular Event Modeling Project 2007. (Accessed NOV, 14, 2007, at http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CVmodeling.pdf ) 86. Rosen CJ. The rosiglitazone story--lessons from an FDA Advisory Committee meeting. N Engl J Med 2007;357(9):844-6. 87. Mele J. Avandia: FDA meta-analysis. Presented at the joint meeting of the Metabolic & Endocrine Advisory Committee and the Drug Safety & Risk Management Advisory Committee held on July 30, 2007. (Accessed JUN, 12, 2008, at http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4308s1-05-fda-mele.ppt.) 88. Joint Meeting Of The Endocrinologic and Metabolic Drugs Advisory Committee And The Drug Safety Management Advisory Committee. 2007. (Accessed JUN, 12, 2008, at http://www.fda.gov/ohrms/dockets/ac/07/transcripts/2007-4308t1-Part4.pdf.) 89. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298(10):1189-95. 90. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298(10):1180-8. 91. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164(19):2097-104. 92. Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22(8):986-93. 93. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007. 94. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298(22):2634-43. 95. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007;16(7):711-25. 96. Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 2008. 97. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 2007;16(5):504-12. 98. Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract 2004;58(9):833-7. 99. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59. 100. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational sudies for causal effects. Biometrika 1983;70(1):41-55. 101. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999;150(4):327-33. 102. Wang J, Donnan PT. Propensity score methods in drug safety studies: practice, strengths and limitations. Pharmacoepidemiol Drug Saf 2001;10(4):341-4. 103. 全民健康保險研究資料庫. 2008. (Accessed at http://www.nhri.org.tw/nhird/.) 104. Storm BL. How should one perform pharmacoepidemiology studies? Choosing among the available alternatives. In: 4, ed. Pharmacoepidemiology: Wiley; 2005:363. 105. Brown AF, Mangione CM, Saliba D, Sarkisian CA. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003;51(5 Suppl Guidelines):S265-80. 106. Chiang CW, Chiu HF, Chen CY, Wu HL, Yang CY. Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003. J Clin Pharm Ther 2006;31(1):73-82. 107. 中央健康保險局 藥品幾付規定 CH2. 心臟血管及腎臟藥物. 2008. (Accessed JUL, 12, 2008, at http://www.nhi.gov.tw/02hospital/hospital_file/chap2.doc.) 108. Chuang LM, Tsai ST, Huang BY, Tai TY. The current state of diabetes management in Taiwan. Diabetes Res Clin Pract 2001;54 Suppl 1:S55-65. 109. Dahabreh IJ. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008;5(2):116-20. 110. Rosen CJ. The Rosiglitazone Story -- Lessons from an FDA Advisory Committee Meeting. N Engl J Med 2007. 111. 胡賦強老師上課講義. 112. WHO ATC/DDD Index 2008. (Accessed FEB, 27, 2008, at http://www.whocc.no/atcddd/indexdatabase/index.php?query=A10BG.) 113. Culman J, Zhao Y, Gohlke P, Herdegen T. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 2007;28(5):244-9. 114. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103(22):2668-73. 115. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27(8):1879-84. 116. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25(11):2058-64. 117. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007;49(16):1696-704. 118. Hartung DM, Touchette DR, Bultemeier NC, Haxby DG. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy 2005;25(10):1329-36. 119. Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 2005;28(1):20-6. 120. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008;29(1):12-20. 121. Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003;17(6):314-22. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26620 | - |
dc.description.abstract | 研究背景 心血管疾病是第二型糖尿病患者死亡的主因。而近期國外的綜合分析(meta-analysis)顯示,用來治療第二型糖尿病的藥物胰島素增敏劑-- rosiglitazone可能增加心血管疾病的發生率(例如:心肌梗塞、心衰竭),甚至增加因心血管事件而導致的死亡率。同類藥物pioglitazone的大型臨床試驗,以心血管事件為其最終分析之主要標的,研究顯示不盡相同的結果。因此釐清此類藥品在心血管的副作用為目前重要之議題。目前國內尚無相關的全國性糖尿病藥物造成心血管副作用之藥物流行病學之研究發表,本研究對於國內病人臨床用藥之評估與醫療政策等觀點能夠提供新的思維與參考。
研究目的 針對第二型糖尿病病人,探討單獨或併服使用胰島素增敏劑(thiazolidindiones, TZD)之病人,相較於使用其他口服降血糖藥物之病人心血管住院事件發生的風險,同時也針對目前市場上兩種胰島素增敏劑rosiglitazone與pioglitazone進行分析比較,試圖了解兩者在心血管副作用上是否有class effect。 研究方法 本研究為一回溯性世代研究,以健保資料庫2005年100萬人歸人檔為研究材料,針對2003年7月至2006年12月間,18歲以上,第一次使用糖尿病藥物之病患為研究對象。第一部分以研究期間使用過與未使用過TZD類藥物之病人做分組,進行背景資料的描述性分析,探討兩組病人在人口統計學、臨床用藥傾向上的不同。第二部分利用time dependent Cox proportional hazard regression model來進行存活分析,主要研究終點為急性心肌梗塞以及心臟血管手術之住院事件的發生,次要研究終點則為中風之住院事件以及心衰竭造成之住院事件。探討曾經使用或正在使用此類TZD藥物對於三個研究終點的影響,並將rosiglitazone與pioglitazone個別分析。由於使用TZD之病人在背景上與未使用族群不同,可能對研究結果造成影響,我們針對TZD的使用建立propensity score,並納入回歸模式來進行統計校正。 研究結果 經過篩選後,資料庫中共有20861位符合研究條件的病人,第一部分研究結果,研究期間有使用過TZD的病人相較未使用者有著年齡較輕,追蹤時間較長,男性居多,在糖尿病用藥及心血管用藥比例較高的特質。而使用rosiglitazone與pioglitazone的病人也在用藥傾向及開方型態上有所不同。第二部分研究結果中,針對心肌梗塞以及心臟血管手術事件分析,並校正過可能之干擾因子後,顯示曾暴露過TZD類藥物之病人相較於未暴露者發生事件的hazard ratio為1.47 (95% CI=1.01-2.13, p=0.044),若將rosiglitazone與pioglitazone分開討論,使用rosiglitazone存在較高之罹病風險,hazard ratio為1.65-1.68,而Pioglitazone對於心肌梗塞以及心臟手術事件則沒有顯著影響。在回溯性分析使用rosiglitazone的病人以及發生心肌梗塞或者心臟手術事件病人的資料,發現可能增加rosiglitazone使用病人發生事件的風險因素,包括較嚴重的高血脂問題以及缺血性心臟病。中風事件的分析中,由propensity score的結果可知,傾向使用TZD類藥物之病人在背景資料上即存在較高罹患中風之風險,但正在使用TZD類藥物的病人對於中風有一保護的趨勢,hazard ratio=0.51 (95% CI=0.24-1.08, p=0.08)。最後心衰竭事件的分析,不論將TZD類藥物合併討論或將兩個藥物分開討論,是否使用藥物與心衰竭事件的發生並無顯著相關。 結論 研究期間有使用過TZD的病人相較於未使用者,在人口統計學、用藥及住院的背景資料有許多不同之處,而使用rosiglitazone與pioglitazone之病人也在用藥傾向及開方型態上有所不同。曾經使用TZD類藥物,尤其是其中的rosiglitazone,對於心肌梗塞以及心臟手術事件的發生存在較高風險,而對於中風的住院事件與在心衰竭事件的分析上,TZD類藥物則沒有達到顯著影響,但使用TZD類藥物對於中風事件似乎有一保護的趨勢。本研究成果顯示對於已有缺血性心臟病高風險,高血脂控制不佳之病人,對於rosiglitazone此類的糖尿病藥物選用必須更加謹慎,或選擇替代藥品。並建議在中風事件的研究可以全國資料庫作為樣本,篩選出更多病例做進一步分析,獲得更明確的結果。 | zh_TW |
dc.description.abstract | Background
Cardiovascular disease is one of the main causes of death in patients with type II diabetes. Meta-analysis of several clinical trials have raised concerns about increasing risk of myocardial infarction and death from cardiovascular causes in patients treated with rosiglitazone, a drug for diabetes mellitus in the class of thiazolidinedione (TZD). However, a large-scale clinical trial about pioglitazone using time to the occurrence of macrovascular events or death as the primary endpoint focused on has demonstrated a protective effect of pioglitazone on cardiovascular events. Due to lack of national studies examining the effect of TZD on the cardiovascular risk, we conducted the current study to provide a reference for clinical drug safety evaluation and medical policies decision. Objective The study aimed to assess the risk of cardiovascular events between patients who used and who did not use TZD as mono-therapy or combination therapy for DM; and to compare the cardiovascular side effects between rosiglitazone and pioglitazone in order to identify if there was a class effect in the two drugs. Methods This was a retrospective cohort study. We used the National Health Insurance Research Database (NHIRD) to establish a cohort of patients with type 2 diabetes, aged 18 years and older, who initiated any anti-diabetic agents between July 2003 and December 2006. Only patients who didn’t take any antidiabetic agents before were included. Descriptive analysis. The two comparison groups: (1) TZD group is defined as those patients who had any claims for TZDs during our study period, and (2) non-TZD group. We compared the pattern of antidiabetic medication use,, demographic and clinical characteristics, and risk factor for CVD events between the two groups. We also compare the difference in prescription pattern between rosiglitazone users and pioglitazone users。 Analysis for the relation between TZD use and cardiovascular events. Our primary end point was time to acute myocardial infarction (AMI) and coronary revascularization (CR). Our secondary end points were hospitalizations for stroke or congestive heart failure (CHF). We constructed two time dependent Cox proportional hazards models to evaluate the hazard ratio (HR) of TZD use for each study end points we were interested in. One of the models was constructed to estimate the HR for patients who had ever exposed to TZDs (TZD ever users), and the other one for patients who were current user of TZDs (TZD current user). Because of the different baseline characteristics between the TZD and non-TZD groups, we used the propensity score for the statistic matching to decrease the confounding effects from indication of use. We also conducted statistical analysis to identify the impact of rosiglitazone and pioglitazone on different end points separately. Results A total of 20861 eligible patients were identified from the NHIRD. Compared with the non-TZD group, patients in the TZD group were younger, male dominant, treated with more antidiabetic agents and cardiovascular agents use, and were followed for a longer time. There were different patterns of prescription and clinical characteristics between rosiglitazone users and pioglitazone users. After adjusting several confounding factors, patients exposed to TZDs were more likely than those without to have hospitalization for AMI or CR (HR = 1.47, 95% CI=1.01-2.13, p=0.044). If we analyzed the impact of rosiglitazone and pioglitazone separately, rosiglitazone use was associated with a higher risk for AMI or CR (adjusted HR =1.65, 1.68). There was no significant effect of pioglitazone on risks for AMI or CR. The analyses of baseline characteristics of patients who used rosiglitazone or who suffered from AMI or CR retrospectively revealed that patients treated with rosiglitazone were more likely to be younger, and to use second line oral hypolglycemic agents,and lipid-lowering agents. Cox regression analysis revealed that patients who had higher propensity to use TZDs were more likely to have hospitalization for stroke. TZD current user may be less likely to have stroke event (Adjusted HR = 0.51, 95% CI=0.24-1.08, p=0.08). TZD use had no significant impact on hospitalization for CHF. Conclusions Our findings suggest significant differences in demographic and clinical characteristics between the TZD group and the non-TZD group; and significant different prescription patterns between rosiglitazone users and pioglitazone users. Moreover, patients who had ever exposed to TZD, especially rosiglitazone, were at elevated risk of hospitalization for AMI or CR. We recommend that patients who are already in the high risk for ischemic heart disease, who have poor controlled hyperlipidemia may have an additional risk , and should use the rosiglitazone carefully and consider alternative therapies. The current study failed to provide evidence to support an association between TZD use and hospitalization for stroke or HF. It warrants to exam the prediction of TZD to stroke events in further studies according our findings of a marginally significant relationship between TZD and stroke. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T07:17:48Z (GMT). No. of bitstreams: 1 ntu-97-R95451001-1.pdf: 1004757 bytes, checksum: c962e72c4151cda2e6f0d6883167148a (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 謝辭 i
中文摘要 ii Abstract iv 目錄 vii 圖目錄 xi 表目錄 xii 第 1 章 前言 1 第 2 章 文獻探討 3 第 1 節 糖尿病流行病學與治療學 3 2.1.1 糖尿病在台灣地區與世界之流行病學 3 2.1.2 糖尿病與心血管疾病 3 2.1.3 糖尿病治療學 6 第 2 節 口服糖尿病藥物thiazolidinedione類藥物介紹 10 2.2.1 TZD類藥物之藥理作用39 10 2.2.2 TZD類藥物之藥效學比較 11 2.2.3 TZD類藥物之副作用 17 第 3 節 糖尿病藥品與心血管疾病 20 2.3.1 非TZD類藥物與心血管疾病 20 2.3.2 TZD類藥物與心血管疾病 21 第 4 節 TZD類藥物於心血管疾病之綜合分析與流行病學研究 23 2.4.1 TZD類藥物與心血管疾病之綜合分析 (meta analysis) 23 2.4.2 各國利用保險資料庫對於TZD藥物與心血管疾病之研究 24 第 5 節 從長期大型臨床試驗討論TZD類藥物之心臟血管風險 30 第 6 節 Propensity score (趨勢得分法) 31 第 3 章 研究方法 33 第 1 節 研究材料 33 3.1.1 台灣地區100萬人健保資料庫承保抽樣歸人檔 33 第 2 節 研究族群建立與研究目標訂定 34 3.2.1 研究架構 34 3.2.2 研究對象納入與排除條件 34 3.2.3 研究終點(endpoint)事件定義 35 3.2.4 研究期間定義 36 3.2.5 研究分組定義 37 3.2.6 背景資料追蹤(藥物暴露及干擾因子) 38 3.2.7 統計分析 39 3.2.8 資料庫之限制 42 第 4 章 研究結果 44 第 1 節 研究族群分組與背景資料分析 44 4.1.1 研究族群背景分析 44 4.1.2 研究族群分組結果 45 4.1.3 TZD組與non-TZD組之背景資料分析 46 4.1.4 TZD組與non-TZD組之用藥及住院資料分析 47 4.1.5 Rosiglitazone組與pioglitazone組病人之背景資料分析 51 4.1.6 Rosiglitazone組與pioglitazone組之用藥資料分析 51 4.1.7 Rosiglitazone組與pioglitazone組病人在門診開方型態之比較 54 第 2 節 主要研究終點--心肌梗塞及心臟血管手術事件與TZD類藥物 57 4.2.1 心肌梗塞以及心臟血管手術事件之研究對象與粗發生率 57 4.2.2 針對心肌梗塞以及心臟血管手術事件之propensity score 57 4.2.3 CV-TZD組與CV-non-TZD組進行存活分析 59 4.2.4 CV-rosiglitazone組與CV-pioglitazone組在心肌梗塞以及心臟血管手術事件之存活分析 61 第 3 節 次要研究標的—中風事件與TZD藥物 69 4.3.1 中風事件存活分析之研究對象與粗發生率 69 4.3.2 針對中風事件族群之propensity score 69 4.3.3 Stroke-TZD組與stroke-non-TZD組進行存活分析之結果 71 4.3.4 Stroke-rosiglitazone組與stroke-pioglitazone組在中風事件之存活分析結果 74 第 4 節 次要研究標的—心衰竭事件與TZD藥物 81 4.4.1 心衰竭事件存活分析之研究對象與粗發生率 81 4.4.2 心衰竭事件存活分析之propensity score 81 4.4.3 HF-TZD組與HF-non-TZD組病人心衰竭事件之存活分析 82 4.4.4 HF-rosiglitazone組與HF-pioglitazone組病人在心衰竭事件之存活分析結果 85 第 5 章 討論 92 第 1 節 TZD類藥物於糖尿病人的使用 92 5.1.1 TZD組與non-TZD組病人之藥物使用 92 5.1.2 Rosiglitazone組與pioglitazone組之藥物使用型態分析 93 第 2 節 Propensity score與各研究終點之關係 98 5.2.1 Propensity score與回歸模式 98 5.2.2 Propensity score模式之變項以及其在不同研究終點所代表之病人特性 99 第 3 節 心肌梗塞以及心臟血管手術事件與TZD類藥物 100 5.3.1 TZD類藥物與心肌梗塞以及心臟血管手術事件 100 5.3.2 與本研究結果不同之資料庫研究與綜合分析 101 5.3.3 Current user模式與ever user模式分析結果 103 5.3.4 與rosiglitazone組病人相關之回溯性分析與臨床使用建議 104 第 4 節 中風事件與TZD類藥物 110 5.4.1 TZD與中風事件 110 第 5 節 心衰竭事件與TZD類藥物 112 5.5.1 TZD類藥物與心衰竭事件 112 第 6 節 其他口服糖尿病藥物與本研究之研究終點相關性 116 第 7 節 本研究相較於其他研究之優點與研究限制 117 5.7.1 研究限制 117 5.7.2 研究優點與特色 117 第 6 章 結論與建議 118 參考資料 119 附錄1 存活分析資料整理步驟 129 | |
dc.language.iso | zh-TW | |
dc.title | 胰島素增敏劑對於第二型糖尿病病人心臟血管副作用之藥物流行病學研究 | zh_TW |
dc.title | Pharmacoepidemiology Study of Thiazolidinediones on Type II Diabetes Mellitus Patients – Risk Analysis of Cardiovascular Related Adverse Effects | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 高淑芬,沈麗娟 | |
dc.subject.keyword | 胰島素增敏劑,副作用,急性心肌梗塞,中風,心衰竭, | zh_TW |
dc.subject.keyword | thiazolidinedione,adverse event,acute myocardial infection,stroke,heart failure, | en |
dc.relation.page | 132 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2008-07-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 981.21 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。